Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate Ltd has announced its upcoming Annual General Meeting scheduled for October 16, 2025, with director nominations required 45 business days prior. This meeting is a significant event for the company, potentially impacting its governance and strategic direction, and it reflects the company’s ongoing commitment to its stakeholders and market presence.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company specializing in optimizing brain health assessments. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and electronic clinical outcome assessment solutions. Cogstate supports clinical trials with quality assurance services and has been serving biopharmaceutical companies, academic institutions, and healthcare providers globally for over 20 years. In the healthcare market, it focuses on providing digital measures of cognition and has partnered with Eisai to distribute assessments in Asia.
Average Trading Volume: 91,831
Technical Sentiment Signal: Buy
Current Market Cap: A$294.6M
For a thorough assessment of CGS stock, go to TipRanks’ Stock Analysis page.